Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020205717 - RÉGÉNÉRATION DE CARTILAGE À L'AIDE DE CHONDROCYTE ET DE TGF-BÊTA

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

We claim:

1. A method of treating osteoarthritis comprising:

a) generating or obtaining a member of a transforming growth factor superfamily of proteins;

b) generating or obtaining a population of cultured mammalian cells that contain vector encoding a gene, or a population of cultured connective tissue cells that do not contain any vector encoding a gene; and

c) transferring the protein of step a) and the connective tissue cells of step b) by intraarticular injection to an arthritic joint space of a mammalian host with a pharmaceutically acceptable carrier, such that the activity of the combination within the joint space results in regenerating connective tissue.

2. The method according to claim 1, wherein the mammalian cell contains a viral vector.

3. The method according to claim 2, wherein the viral vector is a retroviral vector.

4. The method according to claim 1, wherein the vector is a plasmid vector.

5. The method according to claim 1, wherein the mammalian cells are human embryonic kidney cells or epithelial cells.

6. The method according to claim 5, wherein the mammalian cells are allogeneic or autologous cells.

7. The method of claim 1, wherein the connective tissue cells are chondrocytes.

8. The method according to claim 1, wherein the member of the transformation growth factor (TGF) superfamily is TGF-bI, TGF- 2, TGF- 3, BMP-2, BMP-3, BMP-4, BMP-6, BMP-7, or BMP-9.

9. A method of regenerating hyaline cartilage, comprising:

a) generating or obtaining a member of a transforming growth factor superfamily of proteins;

b) generating or obtaining a population of cultured mammalian cells that contain vector encoding a gene, or a population of cultured connective tissue cells that do not contain any vector encoding a gene; and

c) transferring the protein of step a) and the connective tissue cells of step b) by intraarticular injection to an arthritic joint space of a mammalian host with a pharmaceutically acceptable carrier, such that the activity of the combination within the joint space results in regenerating connective tissue.

10. The method according to claim 9, wherein the mammalian cell contains a viral vector.

11. The method according to claim 10, wherein the viral vector is a retroviral vector.

12. The method according to claim 9, wherein the vector is a plasmid vector.

13. The method according to claim 9, wherein the mammalian cells are human embryonic kidney cells or epithelial cells.

14. The method according to claim 9, wherein the connective tissue cells are chondrocytes.

15. The method according to claim 9, wherein the mammalian cells are allogeneic or autologous cells.

16. The method according to claim 9, wherein the member of the transformation growth factor (TGF) superfamily is TGF-bI, TGF- 2, TGF- 3, BMP-2, BMP-3, BMP-4, BMP-6, BMP-7, or BMP-9.

17. A method of regenerating hyaline cartilage, comprising:

a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily of proteins operatively linked to a promoter;

b) transfecting in vitro a population of cultured allogeneic mammalian cells with said recombinant vector, resulting in a population of transfected allogeneic mammalian cells; and c) transplanting said transfected allogeneic mammalian cells by intraarticular injection to an arthritic joint space of a mammalian host with a pharmaceutically acceptable carrier, such that expression of said DNA sequence within said joint space results in regenerating hyaline cartilage.

18. The method according to claim 17, wherein the member of the transforming growth factor (TGF) superfamily of proteins is TGF-bI, TGF- 2, TGF- 3, BMP-2, BMP-3, BMP-4, BMP-6, BMP-7, or BMP-9.

19. The method according to claim 17, wherein the mammalian cells are human embryonic kidney cells or epithelial cells.

20. A method of treating osteoarthritis, comprising:

a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily of proteins operatively linked to a promoter;

b) transfecting in vitro a population of cultured allogeneic mammalian cells with said recombinant vector, resulting in a population of transfected allogeneic mammalian cells; and c) transplanting said transfected allogeneic mammalian cells by intraarticular injection to an arthritic joint space of a mammalian host with a pharmaceutically acceptable carrier, such that expression of said DNA sequence within said joint space results in regenerating hyaline cartilage.

21. The method according to claim 20, wherein the member of the transforming growth factor (TGF) superfamily of proteins is TGF-bI, TGF- 2, TGF- 3, BMP-2, BMP-3, BMP-4, BMP-6, BMP-7, or BMP-9.

22. The method according to claim 20, wherein the mammalian cells are human embryonic kidney cells or epithelial cells.

23. A method of treating an injury to connective tissue in a joint, comprising:

a) generating or obtaining a member of a transforming growth factor superfamily of proteins;

b) generating or obtaining a population of cultured mammalian cells that contain vector encoding a gene, or a population of cultured connective tissue cells that do not contain any vector encoding a gene; and

c) transferring the protein of step a) and the connective tissue cells of step b) by intraarticular injection to an arthritic joint space of a mammalian host with a pharmaceutically acceptable carrier, such that the activity of the combination within the joint space results in regenerating connective tissue.

24. The method according to claim 23, wherein the mammalian cells are human embryonic kidney cells or epithelial cells.

25. A method of treating an injury to connective tissue in a joint comprising:

a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily of proteins operatively linked to a promoter;

b) transfecting in vitro a population of cultured allogeneic mammalian cells with said recombinant vector, resulting in a population of transfected allogeneic mammalian cells; and c) transplanting said transfected allogeneic mammalian cells by intraarticular injection to an arthritic joint space of a mammalian host with a pharmaceutically acceptable carrier, such that expression of said DNA sequence within said joint space results in regenerating hyaline cartilage.

26. The method according to claim 25, wherein the mammalian cells are human embryonic kidney cells or epithelial cells.